APASL Oncology 2022 (APASL STC in Takamatsu).

In this conference, the tentative programs will be focused on Clinical and basic research in liver diseases including hepatocellular carcinoma (including near-future treatment).

For decades, basic research of the proliferation and progression growth has been performed in hepatocellular carcinoma.

Recently, through many basic research, molecular target drugs, namely, sorafenib, regorafenib, and lenvatinib, have been used for advanced hepatocellular carcinoma.

Now, immune checkpoint inhibitors are also used in advanced hepatocellular carcinoma.

We would like to discuss new therapeutic targets in addition to currently molecular target drugs used in hepatocellular carcinoma.

In addition, we would like to discuss diagnosis and treatment based on basic research on various liver diseases other than hepatocellular carcinoma.

Further information will be announced through this website.

We anticipate active fruitful discussions with you!